Live: Will Hims & Hers Rebound After Tonight’s Q2 Earnings?

Beyond the headline numbers, there are several under-the-radar catalysts that could swing tonight’s reaction for Hims & Hers Health (NYSE:HIMS).

• Eucalyptus Deal Timing. The pending acquisition is slated to close mid-2026, and guidance excludes any contribution. Commentary on the closing window or the reported $450M+ ARR from Australia and Japan would reset the FY2026 $2.80B-$3.00B revenue bar.
• FX and International Mix. Rest-of-World revenue jumped 969% YoY to $78.19M in Q1, introducing meaningful non-USD exposure via ZAVA, Spain, and Canada. Currency swings now materially impact reported growth.
• Novo Nordisk Update. Wegovy distribution talks flagged in Q3 2025 remain unresolved; any progress or termination would shift the GLP-1 thesis meaningfully.
• Options Positioning. The Aug 14 put/call ratio of 1.08 signals defensive hedging, while insiders logged 94 recent transactions, net selling, into the release.

Ahead of tonight’s Q2 report, Hims & Hers Health (NYSE:HIMS) trades near $31.65, with Polymarket now pricing a 62% miss probability, up from the 57% cited earlier.

Bull Case

• Subscribers reached nearly 2.6 million, and international revenue surged 969% YoY to $78.19 million.
• CFO Yemi Okupe guided to a “meaningful step-up in adjusted EBITDA dollars in the third and fourth quarters.”
• Shares rallied 13.76% over the past week, and a $250 million buyback sits ready.

Bear Case

• HIMS missed 5 of the last 6 quarters, averaging -3.41% day-of declines on misses.
• Q1 U.S. revenue fell 8% YoY; GAAP gross margin compressed to 65% from 73%.
• Composite sentiment sits at 29.78 (Bearish), with insiders net selling across 94 recent transactions.

Hims & Hers Health heads into its Q2 earnings report with management guiding for revenue between $680-$700 million.

After the company missed top-line expectations in Q1, investors will want to see a return to stronger growth and execution, as well as evidence that gross margins can recover from the previous quarter’s 65% level.

Prediction markets currently assign a 57% probability that Hims & Hers misses expectations, while Reddit sentiment has turned heavily bearish.

Wall Street’s average price target of $29.23 also implies roughly 8.48% downside from current levels.

Despite this negativity, a strong revenue beat tonight accompanied by stabilizing margins could revive confidence in the company’s healthcare platform and its path toward $6.5 billion in revenue by 2030.

However, a second consecutive miss would strengthen the bearish case and potentially give management an earlier opportunity to deploy its recently authorized share repurchase program.